|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.96 USD | +0.46% |
|
+4.11% | +4.50% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
EBT: Breakdown by Business Segment
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
Pharmaceutical Products | ||||
Operating Income | -25.16M | -35.31M | -68.19M | -98.06M |
Net Income | -26.14M | -32.56M | -61.92M | -86.97M |
D&A | 56K | 157K | 244K | 248K |
EBT | -26.14M | -32.56M | -61.92M | -86.97M |
CAPEX | -441K | -129K | -874K | -1.93M |
Interest Expense | -374K | - | - | - |
Total Assets | 45.1M | 84.18M | 269M | 385M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
EBT | -26.14M | -32.56M | -61.92M | -86.97M |
Operating Income | -25.16M | -35.31M | -68.19M | -98.06M |
Net Income | -26.14M | -32.56M | -61.92M | -86.97M |
CAPEX | -441K | -129K | -874K | -1.93M |
D&A | 56K | 157K | 244K | 248K |
Interest Expense | -374K | - | - | - |
Total Assets | 45.1M | 84.18M | 269M | 385M |
- Stock Market
- Equities
- MBX Stock
- Financials MBX Biosciences, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
